Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.

Cancer research - 1 Oct 2004

Ho Chung-Liang, Kurman Robert J, Dehari Reiko, Wang Tian-Li, Shih Ie-Ming

Abstract excerpt

Molecular genetic changes that are associated with the initiating stage of tumor development are important in tumorigenesis. Ovarian serous borderline tumors (SBTs), putative precursors of low-grade serous carcinomas, are among the few human neoplasms with a high frequency of activating mutations in BRAF and KRAS genes. However, it remains unclear as to how these mutations contribute to tumor progression. To...

Topics

Join the communities discussing this publication.

KRAS gene
Mutation
Ovarian Neoplasms
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins c-raf

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 15466181
DOI: 10.1158/0008-5472.CAN-04-2067

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.PMID 15466181Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.Semantic proximity Read ↗

High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor: A Distinctive Morphology With Abundant Dense Eosinophilic Cytoplasm and Dismal Prognosis.Semantic proximity Read ↗

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.Semantic proximity Read ↗

Molecular genetic analysis of ovarian serous cystadenomas.Semantic proximity Read ↗

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Semantic proximity Read ↗

Low‐grade serous carcinomas of the ovary contain very few point mutationsSemantic proximity Read ↗

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.